Richard W. Paul & Associates’s CRISPR Therapeutics CRSP Stock Holding History

Richard W. Paul & Associates’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-42	Closed	-$1.65K	–	379
2024 Q4	$1.65K	Hold	42	–	–	﹤0.01%	430
2024 Q3	$1.97K	Hold	42	–	–	﹤0.01%	413
2024 Q2	$2.27K	Hold	42	–	–	﹤0.01%	405
2024 Q1	$2.86K	Hold	42	–	–	﹤0.01%	398
2023 Q4	$2.63K	Hold	42	–	–	﹤0.01%	394
2023 Q3	$1.91K	Hold	42	–	–	﹤0.01%	405
2023 Q2	$2.36K	Hold	42	–	–	﹤0.01%	416
2023 Q1	$1.9K	Hold	42	–	–	﹤0.01%	438
2022 Q4	$1.71K	Buy	+42	New	+$2.23K	﹤0.01%	439

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Richard W. Paul & Associates's CRSP Position: Q1 2025 in Review

Richard W. Paul & Associates sold out of CRISPR Therapeutics (CRSP) in Q1 2025, closing a stake of 42 shares — an estimated $1.65K sold.

Richard W. Paul & Associates first reported a position in CRSP in Q4 2022 and held it in 9 quarters. The position peaked at $2.86K in Q1 2024. 396 funds tracked by Wall St. Rank hold CRSP as of Q1 2025.

Richard W. Paul & Associates reported no remaining CRISPR Therapeutics position as of Q1 2025 after selling out during the quarter.
Richard W. Paul & Associates sold 42 CRISPR Therapeutics shares in Q1 2025, an estimated $1.65K.
Richard W. Paul & Associates first reported a position in CRISPR Therapeutics in Q4 2022 and held it in 9 quarters.
Richard W. Paul & Associates's CRISPR Therapeutics position peaked at $2.86K in Q1 2024.
396 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2025.

Based on Richard W. Paul & Associates's 13F filing for Q1 2025, filed 12 May 2025.